Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, parallel-arm Phase III trial of tesofensine in patients with obesity

X
Trial Profile

A randomized, double-blind, placebo-controlled, parallel-arm Phase III trial of tesofensine in patients with obesity

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tesofensine (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms Viking
  • Sponsors Medix
  • Most Recent Events

    • 25 Jun 2021 According to a Saniona media release, discussions with the committee may delay the anticipated final approval decision from COFEPRIS into 2022.
    • 25 Jun 2021 According to a Saniona media release, the tesofensine application was reviewed by a COFEPRIS technical committee and was unable to provide a favorable opinion and cited the need for additional information regarding certain topics, including weight loss maintenance. The company ill gather the requested information and continue discussions with the committee as soon as possible.
    • 23 Dec 2019 According to a Saniona media release, company has submitted a new drug application to the Mexican food and drug administration for approval of tesofensine for the treatment of patients with obesity.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top